TY - JOUR
T1 - Diagnosis of Latent Mycobacterium tuberculosis Infection in the Era of Interferon Gamma Release Assays
AU - McCormick-Baw, Clare
AU - Hollaway, Rita
AU - Cavuoti, Dominick
N1 - Publisher Copyright:
© 2018 Elsevier Inc.
PY - 2018/9/1
Y1 - 2018/9/1
N2 - Mycobacterium tuberculosis (MTB), an acid-fast bacterium, is a leading cause of respiratory illness and death worldwide. Individuals can be latently infected and can harbor the organism without clinical evidence of disease for years. Screening and treatment of numerous populations, including health care workers, recent contacts of actively infected individuals, immunocompromised individuals, children, and immigrants from countries where MTB is endemic, is essential to eradicate the infection by 2050, as the World Health Organization envisions. Detection of active and latent infection historically has utilized tuberculin skin tests and other clinical findings. Interferon gamma release assays can test whether a patient has had MTB exposure with improved sensitivity and specificity over tuberculin skin testing. This article reviews the history of MTB testing, compares available interferon gamma release assays, and discusses the new developments related to latent-MTB infection testing.
AB - Mycobacterium tuberculosis (MTB), an acid-fast bacterium, is a leading cause of respiratory illness and death worldwide. Individuals can be latently infected and can harbor the organism without clinical evidence of disease for years. Screening and treatment of numerous populations, including health care workers, recent contacts of actively infected individuals, immunocompromised individuals, children, and immigrants from countries where MTB is endemic, is essential to eradicate the infection by 2050, as the World Health Organization envisions. Detection of active and latent infection historically has utilized tuberculin skin tests and other clinical findings. Interferon gamma release assays can test whether a patient has had MTB exposure with improved sensitivity and specificity over tuberculin skin testing. This article reviews the history of MTB testing, compares available interferon gamma release assays, and discusses the new developments related to latent-MTB infection testing.
UR - http://www.scopus.com/inward/record.url?scp=85051643442&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85051643442&partnerID=8YFLogxK
U2 - 10.1016/j.clinmicnews.2018.08.005
DO - 10.1016/j.clinmicnews.2018.08.005
M3 - Article
AN - SCOPUS:85051643442
SN - 0196-4399
VL - 40
SP - 139
EP - 144
JO - Clinical Microbiology Newsletter
JF - Clinical Microbiology Newsletter
IS - 17
ER -